07-01 Grifols S A : reorganizes its operating model to accelerate execution of its strategic roadmap PU
06-29 Grifols S A : doses first participant in Phase 3 study evaluating novel subcutaneous therapy for alpha1-antitrypsin deficiency PU
06-26 Delisting (ISIN NUMBER: XS2077646391 (Reg. S) / XS2077647365 (144A)) AQ
06-26 Partial Redemption (ISIN NUMBER: XS2805351843 (Reg. S) / XS2805352064 (144A)) AQ
06-22 Grifols, S.A. Announces Board and Committee Changes, Effective June 19, 2026 CI
06-22 Changes in the Composition of the Board of Directors and Board Committees AQ
06-19 Bestinver Securities Lowers Grifols PT, Keeps at Buy MT
06-18 Grifols S A : Shareholders approve key resolutions at the 2026 Annual General Shareholders’ Meeting PU
06-18 Grifols Communications - Resolutions adopted by the Board of Directors AQ
06-15 Grifols Launches Fesilty in the U.S CI
06-15 Grifols Launches Fesilty Blood Clotting Concentrate in US MT
06-15 Grifols Launches FESILTY™ (fibrinogen, human-chmt) in the U.S. AQ
06-12 Grifols S A : Egypt continues its growth plan through 2029 with an additional investment of €180 million PU
06-03 Grifols S A : breaks ground on new manufacturing site in Spain PU
05-26 Grifols S A : doubles the number of positions in its vocational training program over the past year in Spain PU
05-26 Grifols' Insatiable Appetite Zonebourse
05-25 CaixaBank Trims Grifols' PT, Maintains Buy Rating MT
05-15 PRESS DIGEST-Canada - May 18 RE
05-15 Ordinary General Shareholders' Meeting AQ
05-08 Grifols: FCFs didn't impress; rebuilding trust isn't going to be easy Alphavalue
05-08 Grifols Disappoints, Shares Lose Ground Zonebourse
05-08 Moody's Changes Grifols Outlook to Positive MT
05-08 Grifols Q1 Adjusted Profit Rises, Revenue Falls MT
05-08 Grifols S A : Conference call transcript (a065ff21 61b9 2f2c 67fc 1284cdbb08dct1778229612320) PU
05-07 Grifols, S.A. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
No results match your criteria